{"id":"NCT01179672","sponsor":"Eli Lilly and Company","briefTitle":"A Study in Participants With Diabetic Peripheral Neuropathic Pain in China","officialTitle":"Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China: Duloxetine Versus Placebo","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-04","primaryCompletion":"2013-08","completion":"2013-08","firstPosted":"2010-08-11","resultsPosted":"2014-07-14","lastUpdate":"2014-10-13"},"enrollment":405,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Neuropathy, Painful"],"interventions":[{"type":"DRUG","name":"Duloxetine","otherNames":["Cymbalta","LY248686"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Duloxetine","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this trial is to assess the efficacy of duloxetine 60 milligrams (mg) once daily (QD) compared with placebo, on the change in pain severity from baseline to 12 weeks as measured by the weekly mean of the daily pain scores recorded in the participant's diary in participants with diabetic peripheral neuropathic pain.","primaryOutcome":{"measure":"Mean Change From Baseline at 12-Week Endpoint in the Weekly Mean of Pain Severity Score","timeFrame":"Baseline, 12 weeks","effectByArm":[{"arm":"Duloxetine","deltaMin":-2.4,"sd":0.14},{"arm":"Placebo","deltaMin":-1.97,"sd":0.14}],"pValues":[{"comp":"OG000 vs OG001","p":"0.030"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":12},"locations":{"siteCount":15,"countries":["China"]},"refs":{"pmids":["25939897"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":202},"commonTop":["Nausea","Dizziness","Decreased appetite","Somnolence","Hyperlipidaemia"]}}